Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Replimune Group Trading Up 2.6 %
NASDAQ:REPL opened at $11.23 on Thursday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $12.97. The stock has a fifty day moving average price of $11.48 and a two-hundred day moving average price of $9.64.
Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. As a group, equities research analysts forecast that Replimune Group, Inc. will post -3.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Man behind OpenAI makes shocking new bet
From DTI | Ad
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI…
But there’s a far lesser known investment he’s making that could put OpenAI to shame.
In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI…
And the US Military… not to mention hundreds of other giant companies around the globe.
To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office…
Which ordered the government to take this incredible new technology seriously.
Check out our report right here.
Several institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group in the second quarter valued at $57,000. Arizona State Retirement System purchased a new position in Replimune Group during the second quarter worth about $108,000. Quest Partners LLC boosted its stake in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after buying an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in shares of Replimune Group during the 3rd quarter valued at about $133,000. Institutional investors and hedge funds own 92.53% of the company's stock.
Analysts Set New Price Targets
REPL has been the subject of several research analyst reports. Roth Capital upgraded shares of Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Replimune Group in a research report on Tuesday, November 12th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, September 24th. Finally, Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 target price on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $16.80.
Get Our Latest Analysis on Replimune Group
About Replimune Group
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
